Date: 2015-04-20
Type of information: Licensing agreement
Compound: optimized AAV vectors
Company: Applied Genetic Technologies Corporation (USA - FL) 4D Molecular Therapeutics (4DMT) (USA - CA)
Therapeutic area: Ophtalmological diseases
Type agreement: licensing collaboration
Action mechanism: gene therapy
Disease: ophtalmological diseases
Details: * On April 20, 2015, Applied Genetic Technologies Corporation and 4D Molecular Therapeutics (4DMT), leaders in next-generation adeno-associated virus (AAV) gene therapy vector discovery and product development, announced a collaboration and license agreement to discover and develop optimized AAV vectors to treat specific ophthalmic disease indications with high unmet medical need. As part of the agreement, 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel vectors. AGTC’s lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC is also pursuing pre-clinical development of treatments for wet AMD using the company’s experience in ophthalmology to expand into disease indications with larger markets.
Financial terms: Financial details were not disclosed.
Latest news:
